Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Activation of Trace Amine-Associated Receptor 1 stimulates an anti-apoptotic signal cascade via ERK1/2.

Shi X, Swanson TL, Miner NB, Eshleman AJ, Janowsky A.

Mol Pharmacol. 2019 Aug 13. pii: mol.119.116798. doi: 10.1124/mol.119.116798. [Epub ahead of print]

2.

Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists.

Tosh DK, Ciancetta A, Mannes P, Warnick E, Janowsky A, Eshleman AJ, Gizewski E, Brust TF, Bohn LM, Auchampach JA, Gao ZG, Jacobson KA.

ACS Omega. 2018 Oct 31;3(10):12658-12678. doi: 10.1021/acsomega.8b01237. Epub 2018 Oct 4.

3.

Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters.

Eshleman AJ, Nagarajan S, Wolfrum KM, Reed JF, Swanson TL, Nilsen A, Janowsky A.

Psychopharmacology (Berl). 2019 Mar;236(3):939-952. doi: 10.1007/s00213-018-5059-5. Epub 2018 Nov 5.

PMID:
30397775
4.

Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors.

Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A.

Biochem Pharmacol. 2018 Dec;158:27-34. doi: 10.1016/j.bcp.2018.09.024. Epub 2018 Sep 25.

PMID:
30261175
5.

Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.

Provencher BA, Eshleman AJ, Johnson RA, Shi X, Kryatova O, Nelson J, Tian J, Gonzalez M, Meltzer PC, Janowsky A.

J Med Chem. 2018 Oct 25;61(20):9121-9131. doi: 10.1021/acs.jmedchem.8b00542. Epub 2018 Oct 4.

PMID:
30240563
6.

Verification of a genetic locus for methamphetamine intake and the impact of morphine.

Eastwood EC, Eshleman AJ, Janowsky A, Phillips TJ.

Mamm Genome. 2018 Apr;29(3-4):260-272. doi: 10.1007/s00335-017-9724-5. Epub 2017 Nov 10.

7.

Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters.

Tosh DK, Janowsky A, Eshleman AJ, Warnick E, Gao ZG, Chen Z, Gizewski E, Auchampach JA, Salvemini D, Jacobson KA.

J Med Chem. 2017 Apr 13;60(7):3109-3123. doi: 10.1021/acs.jmedchem.7b00141. Epub 2017 Mar 20.

8.

Structure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release.

Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Swanson T, Johnson RA, Janowsky A.

J Pharmacol Exp Ther. 2017 Jan;360(1):33-47. Epub 2016 Oct 31.

9.

Genetic Polymorphisms Affect Mouse and Human Trace Amine-Associated Receptor 1 Function.

Shi X, Walter NA, Harkness JH, Neve KA, Williams RW, Lu L, Belknap JK, Eshleman AJ, Phillips TJ, Janowsky A.

PLoS One. 2016 Mar 31;11(3):e0152581. doi: 10.1371/journal.pone.0152581. eCollection 2016.

10.

Rigid Adenine Nucleoside Derivatives as Novel Modulators of the Human Sodium Symporters for Dopamine and Norepinephrine.

Janowsky A, Tosh DK, Eshleman AJ, Jacobson KA.

J Pharmacol Exp Ther. 2016 Apr;357(1):24-35. doi: 10.1124/jpet.115.229666. Epub 2016 Jan 26.

11.

The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice.

Carbonaro TM, Eshleman AJ, Forster MJ, Cheng K, Rice KC, Gatch MB.

Psychopharmacology (Berl). 2015 Jan;232(1):275-84. doi: 10.1007/s00213-014-3658-3. Epub 2014 Jul 3.

12.

Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro.

Janowsky A, Eshleman AJ, Johnson RA, Wolfrum KM, Hinrichs DJ, Yang J, Zabriskie TM, Smilkstein MJ, Riscoe MK.

Psychopharmacology (Berl). 2014 Jul;231(14):2771-83. doi: 10.1007/s00213-014-3446-0. Epub 2014 Feb 2.

13.

Effect of Iboga alkaloids on ยต-opioid receptor-coupled G protein activation.

Antonio T, Childers SR, Rothman RB, Dersch CM, King C, Kuehne M, Bornmann WG, Eshleman AJ, Janowsky A, Simon ER, Reith ME, Alper K.

PLoS One. 2013 Oct 16;8(10):e77262. doi: 10.1371/journal.pone.0077262. eCollection 2013.

14.

Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.

Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB.

Psychopharmacology (Berl). 2014 Mar;231(5):875-88. doi: 10.1007/s00213-013-3303-6. Epub 2013 Oct 19.

15.

Substituted methcathinones differ in transporter and receptor interactions.

Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A.

Biochem Pharmacol. 2013 Jun 15;85(12):1803-15. doi: 10.1016/j.bcp.2013.04.004. Epub 2013 Apr 10.

16.

GABAB receptor activation attenuates the stimulant but not mesolimbic dopamine response to ethanol in FAST mice.

Holstein SE, Li N, Eshleman AJ, Phillips TJ.

Behav Brain Res. 2013 Jan 15;237:49-58. doi: 10.1016/j.bbr.2012.09.006. Epub 2012 Sep 13.

17.

Melittin initiates dopamine transporter internalization and recycling in transfected HEK-293 cells.

Keith DJ, Wolfrum K, Eshleman AJ, Janowsky A.

Eur J Pharmacol. 2012 Sep 5;690(1-3):13-21. doi: 10.1016/j.ejphar.2012.05.020. Epub 2012 Jun 5.

18.

Abuse liability profile of three substituted tryptamines.

Gatch MB, Forster MJ, Janowsky A, Eshleman AJ.

J Pharmacol Exp Ther. 2011 Jul;338(1):280-9. doi: 10.1124/jpet.111.179705. Epub 2011 Apr 7.

19.

Melittin stimulates fatty acid release through non-phospholipase-mediated mechanisms and interacts with the dopamine transporter and other membrane-spanning proteins.

Keith DJ, Eshleman AJ, Janowsky A.

Eur J Pharmacol. 2011 Jan 15;650(2-3):501-10. doi: 10.1016/j.ejphar.2010.10.023. Epub 2010 Oct 20.

20.

Uptake and release of neurotransmitters.

Janowsky A, Neve K, Eshleman AJ.

Curr Protoc Neurosci. 2001 May;Chapter 7:Unit7.9. doi: 10.1002/0471142301.ns0709s02.

PMID:
18428535
21.

Lobeline effects on tonic and methamphetamine-induced dopamine release.

Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A.

Biochem Pharmacol. 2008 Mar 15;75(6):1411-5. doi: 10.1016/j.bcp.2007.11.019. Epub 2007 Dec 4.

22.

Hydrogen ion concentration differentiates effects of methamphetamine and dopamine on transporter-mediated efflux.

Wilhelm CJ, Johnson RA, Eshleman AJ, Janowsky A.

J Neurochem. 2006 Feb;96(4):1149-59. Epub 2006 Jan 17.

23.

Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine).

Warden SJ, Bliziotes MM, Wiren KM, Eshleman AJ, Turner CH.

Mol Cell Endocrinol. 2005 Oct 20;242(1-2):1-9. Review.

PMID:
16085354
24.

Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells.

Fiala M, Eshleman AJ, Cashman J, Lin J, Lossinsky AS, Suarez V, Yang W, Zhang J, Popik W, Singer E, Chiappelli F, Carro E, Weinand M, Witte M, Arthos J.

J Neurovirol. 2005 Jul;11(3):281-91.

PMID:
16036808
25.

Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.

Wilhelm CJ, Johnson RA, Lysko PG, Eshleman AJ, Janowsky A.

J Pharmacol Exp Ther. 2004 Sep;310(3):1142-51. Epub 2004 Apr 21.

PMID:
15102929
26.

Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding, distribution, and function in female macaques.

Lu NZ, Eshleman AJ, Janowsky A, Bethea CL.

Mol Psychiatry. 2003 Mar;8(3):353-60.

PMID:
12660809
27.
28.

Mapping genes that regulate density of dopamine transporters and correlated behaviors in recombinant inbred mice.

Janowsky A, Mah C, Johnson RA, Cunningham CL, Phillips TJ, Crabbe JC, Eshleman AJ, Belknap JK.

J Pharmacol Exp Ther. 2001 Aug;298(2):634-43.

PMID:
11454925
29.

NMDA receptor subunit mRNA and protein expression in ethanol-withdrawal seizure-prone and -resistant mice.

Mason JN, Eshleman AJ, Belknap JK, Crabbe JC, Loftis JM, Macey TA, Janowsky A.

Alcohol Clin Exp Res. 2001 May;25(5):651-60.

PMID:
11371713
30.

Drug interactions with the dopamine transporter in cryopreserved human caudate.

Eshleman AJ, Wolfrum K, Mash DC, Christensen K, Janowsky A.

J Pharmacol Exp Ther. 2001 Feb;296(2):442-9.

PMID:
11160629
31.

Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type.

Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A.

J Pharmacol Exp Ther. 1999 May;289(2):877-85.

PMID:
10215666
32.

[3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.

Johnson RA, Eshleman AJ, Meyers T, Neve KA, Janowsky A.

Synapse. 1998 Sep;30(1):97-106.

PMID:
9704886
33.

Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transporters.

Eshleman AJ, Stewart E, Evenson AK, Mason JN, Blakely RD, Janowsky A, Neve KA.

J Neurochem. 1997 Oct;69(4):1459-66.

34.

Characterization of a recombinant human dopamine transporter in multiple cell lines.

Eshleman AJ, Neve RL, Janowsky A, Neve KA.

J Pharmacol Exp Ther. 1995 Jul;274(1):276-83.

PMID:
7616409
35.
36.

Release of dopamine via the human transporter.

Eshleman AJ, Henningsen RA, Neve KA, Janowsky A.

Mol Pharmacol. 1994 Feb;45(2):312-6.

PMID:
7906856
37.

Allosteric regulation by sodium of the binding of [3H]cocaine and [3H]GBR 12935 to rat and bovine striata.

Eshleman AJ, Calligaro DO, Eldefrawi ME.

Membr Biochem. 1993 Jul-Sep;10(3):129-44.

PMID:
8231896
38.
39.

Synthesis of 3-carbamoylecgonine methyl ester analogues as inhibitors of cocaine binding and dopamine uptake.

Kline RH Jr, Wright J, Eshleman AJ, Fox KM, Eldefrawi ME.

J Med Chem. 1991 Feb;34(2):702-5.

PMID:
1995895

Supplemental Content

Loading ...
Support Center